# Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI

Source: https://onco.cc/trials/nct07355231/  
OnCo record `nct07355231` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in lung cancer, run by Xemed LLC, not yet recruiting.

## Summary

Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI is a phase 1/2, interventional study registered as NCT07355231 by Xemed LLC, with a registry enrolment figure of 10 participants, started 2027-03-01 and due to reach its primary completion in 2028-02-29. Interventions recorded: Hyperpolarized xenon MRI. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: Changes in DLCO at 6-month post RT treatment.. Lung eligibility wording from the registry: "* Patients over 18 years with a diagnosis of non-small lung cancer and planned for a definitive course of radiation therapy". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: GuidedRT
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07355231
- Phase: 1/2
- Setting: Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI
- Sponsor: Xemed LLC
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT07355231: https://clinicaltrials.gov/study/NCT07355231

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07355231.json